PTC Therapeutics, Inc.
PTCT
$73.46
-$1.56-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -53.34% | 114.51% | 97.54% | 96.00% | 91.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.34% | 114.51% | 97.54% | 96.00% | 91.12% |
| Cost of Revenue | -13.05% | -32.09% | -32.99% | -23.81% | -26.18% |
| Gross Profit | -68.41% | 518.28% | 359.71% | 338.57% | 371.04% |
| SG&A Expenses | 14.18% | 15.36% | 14.51% | 8.14% | -3.23% |
| Depreciation & Amortization | 150.08% | -59.26% | -86.11% | -92.53% | -94.46% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.13% | -8.32% | -16.68% | -17.82% | -25.08% |
| Operating Income | -107.73% | 683.66% | 821.89% | 550.40% | 410.40% |
| Income Before Tax | -136.18% | 291.84% | 274.16% | 234.82% | 200.87% |
| Income Tax Expenses | -186.53% | 7,840.34% | -138.66% | 353.65% | 184.93% |
| Earnings from Continuing Operations | -131.39% | 287.90% | 265.87% | 231.21% | 202.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.39% | 287.90% | 265.87% | 231.21% | 202.70% |
| EBIT | -107.73% | 683.66% | 821.89% | 550.40% | 410.40% |
| EBITDA | -102.24% | 1,359.53% | 4,270.83% | 6,935.62% | 3,029.36% |
| EPS Basic | -130.87% | 285.92% | 261.83% | 227.01% | 198.37% |
| Normalized Basic EPS | -131.36% | 408.94% | 398.51% | 324.40% | 283.36% |
| EPS Diluted | -136.00% | 263.27% | 243.81% | 210.22% | 184.59% |
| Normalized Diluted EPS | -134.87% | 370.05% | 369.11% | 299.49% | 262.86% |
| Average Basic Shares Outstanding | 3.52% | 2.63% | 2.06% | 2.07% | 2.28% |
| Average Diluted Shares Outstanding | 3.54% | 8.13% | 7.60% | 4.79% | 5.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |